Vaccine Formulation


Our response against COVID-19


In November 2019, a novel coronavirus named Sars-CoV-2 was identified as the cause of pneumonia in a cluster of patients in Wuhan, People’s Republic of China. The World Health Organization characterized this outbreak as a pandemic on March 11th, 2020. At present, there is no vaccine to prevent COVID-19 disease. VFI is collaborating with numerous vaccine developers worldwide in order to accelerate the development of vaccines against COVID-19.

Our role

VFI can provide suitable adjuvants on an open access basis for the preclinical and clinical development of Covid-19 vaccines. VFI can also provide its formulation platform to support vaccine researchers and developers by testing key adjuvants and formulation parameters to optimize Sars-CoV-2 subunit vaccine candidates. Finally, VFI  can conduct immunogenicity study to rapidly evaluate of B and T cell responses in vivo after immunization with adjuvanted Sars-CoV-2 vaccine candidates. 

About us

VFI is a not-for-profit organization created in 2012 and based in Switzerland. VFI’s mission is to facilitate access to adjuvant technologies for the benefit of the global vaccine community, through provision of adjuvants, R&D on vaccine formulations, and training. 

VFI is a partner in several global vaccine development consortia and programmes, contributing to global health with a specific focus on resource-constrained countries.

Contact us at: